IDEX heads into its third-quarter report carrying something it has not had in a while: genuine momentum. Over three consecutive calls, management lifted its full-year organic growth outlook from 1% to 2% up to 5% to 6%, pushed its adjusted EPS range from $8.15 to $8.35 up to $8.70 to $8.85, and raised its margin target. Orders topped $1 billion for the first time. The question now is less about whether demand is real and more about how quickly that record backlog shows up in the income statement, and whether the nascent recovery in the company's short-cycle industrial businesses survived the summer.
The Street is looking for EPS of $2.23 on revenue of $918.6 million, which would represent growth of roughly 10% and 4.6%, respectively, from a year ago. That consensus sits in the upper half of management's $2.20 to $2.25 guidance range, while the whisper number of $2.30 lands above the top end. In other words, the informal bar assumes IDEX does what it has done all year: beat its own guide. Context matters on the comparison to last quarter's $2.32. That figure included about $0.08 of one-time tariff refunds and roughly 130 basis points of margin that will not repeat, so the underlying run rate was closer to the current consensus. A flat sequential headline would not signal a stall.
Health and Science Technologies remains the engine. Orders in that segment surged 47% organically last quarter, driven by data center, semiconductor, and space and defense applications that now account for more than a third of segment revenue. Management booked a large data center pneumatics order for 2027 delivery and said its forward-year backlog was roughly double the level of a year earlier. This quarter should show whether HST can sustain double-digit organic revenue growth and the strong incremental margins it posted in the second quarter. Order growth will naturally cool against tougher comparisons, so the more telling signal is whether management's view of 2027 visibility keeps expanding.
The broader test lies in the other two segments. Fluid and Metering Technologies grew orders 11% but sales only 1% last quarter, with margins slipping against a demanding prior-year comparison. Fire and Safety orders swung sharply positive, but partly on a single aerospace blanket order at Bandit. Management pointed to an improving distribution channel in June and July, the classic bellwether for a short-cycle turn. Validation would look like FMT sales finally catching up to orders, steadier segment margins, and confirmation that the distribution pickup continued through September. Continued softness in agriculture, chemical, energy, dispensing, and European rescue markets would suggest the recovery is narrower than the guidance implies.
The market has been oddly unmoved by all this. Shares slipped 1.3% since the last report while the S&P 500 gained 3.6%, a roughly five-point lag. Yet sentiment has swung from slightly bearish heading into the prior quarter to solidly bullish now, and the stock trades about 9% above its 200-day moving average in a range noticeably higher than the previous quarter's. At $233.86, it sits a few percent below its post-earnings high of $243.80, leaving room to retest that level on a convincing print.
Ultimately, the story hinges on breadth. HST's data center and semiconductor strength looks durable, but the guidance raises increasingly lean on a broad industrial recovery. If FMT and Fire and Safety convert their orders into revenue and management holds or nudges up its full-year outlook despite losing the tariff tailwind, the acceleration narrative stays intact. If the short-cycle turn proves to be a blip, the stock's recent hesitation may look justified.